Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.42 |
| ▸ | GRM5 | P41594 | 3/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2638332 | 0.86 | HSD11B1 (0.44) | PABPC1HSD11B1GRM5 | |
| SCHEMBL3374466 | 0.86 | PBK (0.51) | MEN1KMT2APABPC1GRM5USP2 | |
| SCHEMBL2278187 | 0.82 | GRM5 (0.51) | HSD11B1GRM5 | |
| SCHEMBL2638164 | 0.81 | RAB9A (0.56) | MEN1KMT2APABPC1HSD11B1GRM5 | |
| SCHEMBL2638230 | 0.81 | GRM5 (0.45) | MEN1KMT2APABPC1HSD11B1GRM5 | |
| SCHEMBL1578690 | 0.81 | GRM5 (0.55) | PABPC1GRM5MAPT | |
| SCHEMBL2638142 | 0.81 | EPHX2 (0.46) | PABPC1HSD11B1GRM5 | |
| SCHEMBL2216510 | 0.80 | GRM5 (0.57) | MEN1KMT2APABPC1HSD11B1GRM5 | |
| SCHEMBL2637964 | 0.79 | PABPC1 (0.70) | KMT2APABPC1GRM5MAPT | |
| SCHEMBL2638165 | 0.78 | EPHX2 (0.49) | HSD11B1USP2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2310356-B1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | LUNDBECK & CO AS H (DK) | 2013-08-14 | — | — | EP | claimed |
| US-20100022546-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2010-01-28 | — | — | US | claimed |
| US-8716284-B2 | Adamantyl diamide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2014-05-06 | — | — | US | disclosed |
| EP-2310356-B1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | LUNDBECK & CO AS H (DK) | 2013-08-14 | — | — | EP | disclosed |
| US-20130184277-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2013-07-18 | — | — | US | disclosed |
| US-8389519-B2 | Adamantyl diamide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2013-03-05 | — | — | US | disclosed |
| US-20120270873-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2012-10-25 | — | — | US | disclosed |
| US-20100022546-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270873-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | QDPR, PDE3B, ADM2 | MEN1 78/4885KMT2A 3173/4885PABPC1 3961/4885 |
| US-20130184277-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | QDPR, PDE3B, ADM2 | MEN1 79/4885KMT2A 2991/4885PABPC1 4007/4885 |
| US-20100022546-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | QDPR, ADM2, PDE3B | MEN1 67/4885KMT2A 3089/4885PABPC1 3818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.